White Paper

A Splitting Headache: Trends in Migraine Therapy

Migraine medications are making up a growing portion of pharmacy spend in workers’ comp, driven by an influx of new CGRP antagonist medications to the market over the last few years.

White Paper Summary

A recent trend in drug therapy is the rise of calcitonin gene-related peptide (CGRP) receptor antagonists for the treatment and prevention of migraines.

A relatively new class of drugs, the first CGRP antagonist was approved in 2018, with several more approved in the following
years. As newer medications, CGRP antagonists come with high costs, and their wide adoption in the market has directly impacted workers’ comp, contributing to year-over-year increases in cost per script and cost per claim for migraine therapies.

This trend is not expected to change course, especially when considering the revised treatment recommendations by the
American Headache Society in March 2024, which include CGRP antagonists as first-line treatment for the prevention of migraines.

 

For more content like this from Healthesystems visit their RxInformer clinical journal website.

Healthesystems is a leading provider of Pharmacy Benefit Management (PBM) & Ancillary Benefits Management programs for the workers' compensation industry.

More from Risk & Insurance